Trial Profile
A Randomized, Double-Blind Phase 2b Study to Evaluate the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Mar 2018
Price :
$35
*
At a glance
- Drugs Blisibimod (Primary)
- Indications Systemic lupus erythematosus
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Therapeutic Use
- Acronyms PEARL-SC
- Sponsors Anthera Pharmaceuticals
- 13 Jun 2015 Results from secondary endpoint analyses presented at the 16th Annual Congress of the European League Against Rheumatism.
- 04 Jun 2015 As per an Anthera Pharmaceuticals media release, data from this study will be submitted at the EULAR congress to be held on 06th June 2015, in Rome, Italy.
- 19 Apr 2014 Results published in the Annals of the Rheumatic Diseases.